Skip to main navigation Investors & Media Company Overview We aspire to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Our experienced team brings significant breadth and depth of expertise in drug development, combined with a commitment to develop new treatments for women suffering from uterine fibroids, endometriosis, and infertility, and men suffering from prostate cancer. We are advancing programs in women’s health, including endometriosis-associated pain and egg maturation in assisted reproduction, including in vitro fertilization (IVF), and the prevention of pregnancy. Over time, we intend to expand our development pipeline to include potential treatments for women's health. FDA Approved Drugs: ORGOVYX (relugolix 120 mg), MYFEMBREE (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) Copyright West LLC. Share price minimum 15 minutes delayed. Market cap from previous market close. Press Releases November 23, 2021 Myovant Sciences to Participate in the Evercore ISI 4th Annual HealthCONx Conference Learn more November 8, 2021 Nancy Valente, M.D. Joins Myovant Sciences’ Board of Directors Learn more October 26, 2021 Myovant Sciences Announces Financial Results for Second Quarter of Fiscal Year 2021 and Corporate Updates Learn more View All Events Oct 26, 2021 at 8:30 AM EDT Myovant Sciences Q2 2021 Earnings Conference Call Click here for webcast Presentation Transcript Sep 15, 2021 at 2:35 PM EDT 2021 Baird Global Healthcare Conference Click here for webcast Transcript View All SEC Filings Oct 26, 2021 Quarterly report which provides a continuing view of a company's financial position 10-Q View HTML 0001679082-21-000043.pdf 0001679082-21-000043.rtf 0001679082-21-000043.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA Jul 28, 2021 Quarterly report which provides a continuing view of a company's financial position 10-Q View HTML 0001679082-21-000025.pdf 0001679082-21-000025.rtf 0001679082-21-000025.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA View All TOOLKIT Print Page RSS Feeds Email Alerts Contact Search © 2021 Myovant Sciences GmbH. All rights reserved. Terms of Use Privacy Policy Cookie Policy Compliance & Prescriber Information